Document 1134
 DOCN  M94A1134
 TI    Clarithromycin and zidovudine pharmacokinetic study.
 DT    9412
 AU    Vance E; Guzman J; Bitar M; Kazanjian P; Brigham & Women's
       Hospital/Harvard Med. School, Boston, MA.
 SO    Int Conf AIDS. 1994 Aug 7-12;10(2):201 (abstract no. PB0816). Unique
       Identifier : AIDSLINE ICA10/94371441
 AB    OBJECTIVE: To evaluate the interrelationships between the
       pharmacokinetics of zidovudine (Z) alone and Z+clarithromycin (C) in
       patients with AIDS. METHODS: Twenty volunteers with AIDS and no
       infection with Mycobacterium avium complex (MAC) were admitted to the
       study. Patients received Z (200mg po q 8hr) days 1-4 and C (1000mg po
       bid) given 2 hours before Z on days 2-4. Drug levels of Z were measured,
       at steady state, prior to (phase 1, day 1) and following (phase 2, day
       4) administration of C. Drug levels of C were measured, at steady state,
       on day 4. RESULTS: The pharmacokinetic parameters, Cmax, Tmax, Cmin and
       AUC of Z were not significantly different from day 1-4 (Table 1). The
       pharmacokinetics of C and 14(R)-Hydroxy-C were comparable to historical
       controls (Table 2). TABULAR DATA, SEE ABSTRACT VOLUME. CONCLUSION: There
       is no significant impact on steady state pharmacokinetics of Z by
       addition of C in patients with AIDS. C may delay initial absorption of Z
       but this is unlikely to have clinical relevance.
 DE    Acquired Immunodeficiency Syndrome/METABOLISM
       Clarithromycin/ADMINISTRATION & DOSAGE/*PHARMACOKINETICS  Human
       Zidovudine/ADMINISTRATION & DOSAGE/*PHARMACOKINETICS  MEETING ABSTRACT

       SOURCE: National Library of Medicine.  NOTICE: This material may be
       protected by Copyright Law (Title 17, U.S.Code).